Some pharmacological properties of 4H-3-methylcarboxamide 1,3-benzoxazine-2-one (FI 6654).
D000109:Acetylcholine / Q000494:pharmacology; D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology*; D001143:Arousal / Q000187:drug effects; D001285:Atropine / Q000494:pharmacology; D001464:Barium / Q000494:pharmacology; D004386:Duodenum / Q000187:drug effects; D004569:Electroencephalography; D006168:Guinea Pigs; D006632:Histamine / Q000494:pharmacology; D007082:Ileum / Q000187:drug effects; D007099:Imipramine / Q000494:pharmacology; D066298:In Vitro Techniques; D008297:Male; D051379:Mice; D009119:Muscle Contraction / Q000187:drug effects*; D009130:Muscle, Smooth / Q000187:drug effects*; D009538:Nicotine; D010078:Oxazines / Q000494:pharmacology*; D010208:Papaverine / Q000494:pharmacology; D010830:Physostigmine / Q000494:pharmacology; D011817:Rabbits; D051381:Rats; D012640:Seizures / Q000139:chemically induced; D012701:Serotonin / Q000494:pharmacology
D000928:Antidepressive Agents; D010078:Oxazines; D001464:Barium; D012701:Serotonin; D009538:Nicotine; D001285:Atropine; D006632:Histamine; D010830:Physostigmine; D010208:Papaverine; D000109:Acetylcholine; D007099:Imipramine